Guidance

Guidelines for submitting a nutritional product to the ACBS

Information and advice on submitting a nutritional product to the Advisory Committee for Borderline Substances (ACBS).

• From: Department of Health and Social Care
• Published: 12 April 2019
• Last updated: 1 February 2024
  Show all updates

  1. 1 February 2024

     Removed 'Appendix 2.1: evidence required for type 3 applications' because this document no longer applies.

  2. 9 June 2023

     In section 2.4 of 'Guidance notes for completing an application form for a nutritional product' the MHRA email address has been amended.

  3. 5 May 2023

     Appendix 5 has been updated with new guidance on acceptability studies for inherited metabolic disorders.

  4. 21 November 2022

     Added appendix 8: the scheduling of product applications to an ACBS meeting agenda

  5. 17 November 2022

     Added guidance notes for completing an application form for a nutritional product.

  6. 4 May 2022

     Updated the definitions for type 2 and type 3 applications, in the attachment 'Appendix 2: types of application'.

  7. 4 February 2022

     Updated to remove the requirement to submit a type 3 application for changes to (i) a product’s shelf life and (ii) the location of manufacture.

  8. 12 April 2019

     First published.

Applies to England

Documents

Guidance notes for completing an application form for a nutritional product

MS Word Document, 117 KB

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Appendix 1: categorisation of nutritional products

PDF, 199 KB, 5 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Appendix 2: types of application

PDF, 127 KB, 3 pages

Appendix 3: nutritional legislation

PDF, 160 KB, 5 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Appendix 4: clinical trial information to be applied for type 1 products

PDF, 157 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Appendix 5: acceptability studies

PDF, 91.8 KB, 6 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Appendix 6: products which will not be considered

PDF, 89 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Appendix 7: the mechanism to ensure patients will be protected

PDF, 137 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Appendix 8: the scheduling of product applications to an ACBS meeting agenda

PDF, 56 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This set of documents contains supporting information for use in submitting a nutritional product for consideration by the Advisory Committee for Borderline Substances (ACBS). This includes:

• how nutritional products are categorised by the ACBS
• evidence required for applications
• relevant nutritional legislation

The documents can be used when filling out the nutritional products application form.